



Surgical removal of rheumatoid nodules

Commissioning	The ICB will provide funding for the surgical removal of
decision	rheumatoid nodules for patients who meet the criteria defined
	within this policy. Funding approval for eligible patients must
	be sought from the ICB via the Prior Approval process prior to
	treatment.

Policy Statement:

Requests for funding will only be approved where one of the following criteria are met:

- Significant pain and/or tenderness of nodules
- OR
- Complications such as infection and ulceration

OR

Pressure symptoms including nerve compression or pressure on an organ or tissue

OR

- Its size or position is causing severe functional impairment of activities of daily living**
- ** Significant functional impairment is defined by the ICB as:
 - Symptoms prevent the patient fulfilling vital work or educational responsibilities
 - o Symptoms prevent the patient carrying out vital domestic or carer activities

Rationale:

Rheumatoid nodules are usually referred to an orthopaedic surgeon for excision, most commonly a hand surgeon or upper limb surgeon, depending on the site and after the patient has received counselling about the risk of recurrence.

Separate guidelines will apply for excision of rheumatoid nodules in the lung where a differential diagnosis of malignancy is considered.

Policy Category:
CBA +PA
Who usually applies for funding?
Consultant





Plain English Summary:

Rheumatoid nodules are bumps in the bones which are different to other types of lumps on joints called ganglia. Rheumatoid nodules tend to occur in patients with more severe forms of the disease rheumatoid arthritis (RA). They appear most commonly on the elbow, forearm, fingers and thumbs or other bony areas following an injury. They may be painful or may cause no pain at all and may vary in size. If they are removed by surgery, they may appear again after a time. They can be difficult to treat with medicines or injections into the joint area.

Surgery may be an option for people who have painful or large nodules which affect the ability to perform activities of daily living as outlined in this policy. **Policy Category:**

CBA +PA

Who usually applies for funding?

Consultant





Evidence base:

Rheumatoid Nodules: Dermatologic clinics; Jul 2015; vol. 33 (no. 3); p. 361-371Tilstra, Jeremy S; Lienesch, Douglas W

For further information please contact GLICB.IFR@nhs.net

Date of publication	November 2018
Policy review date	May 2024

Policy sign off:

Reviewing Body	Date of review	
Effective Clinical Commissioning Policy Group	October 2018	
Quality and Governance Committee	14.02.2019	

Version Control:

Version No	Type of Change	Date	Description of Change
0.01	New Policy	22/11/2018	n/a
0.02	Review date	18/05/2021	Evidence base updated;
	Evidence base		Review date agreed at 3
			years.